Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat in Sickle Cell Disease and Nephropathy
2023-510289-28-00Phase 2Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of mitapivat in sickle cell disease (SCD) and nephropathy, sponsored by Agios Pharmaceuticals. Primary endpoint: ACR response at Month 6. Started Oct 2024; status: completed.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)nephropathy
Beyond the preview
Go deeper on 2023-510289-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510289-28-00.